Secondary analysis of a phase 2 trial in comatose patients after cardiac arrest (125 of 160 with samples): acyl-ghrelin vs placebo was associated with a smaller GFAP rise on days 1 and 3; other neuro-biomarkers showed no significant effect after day 0.
Secondary analysisn = 125
Omes et al. Serum biomarkers of postanoxic encephalopathy in relation to ghrelin treatment. A secondary analysis of the GRECO trial